Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024


FDA Provides Clarity on Path to Licensure for Remestemcel-L in SR-aGVHD and Rexlemestrocel-L in End-Stage Heart Failure FDA Provides Clarity on Path to Licensure for Remestemcel-L in SR-aGVHD and Rexlemestrocel-L in End-Stage Heart Failure

Read more here:
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024

Related Posts